Unicycive Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing therapies for kidney disease. The company's pipeline consists of two product candidates: oxylanthanum carbonate, a next-generation phosphate binder for treating hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a novel drug candidate for the treatment of acute kidney injury. Both assets were licensed from Spectrum Pharmaceuticals and Sphaera Pharma, respectively. Unicycive utilizes a business model of in-licensing technologies to pursue regulatory approval and commercialization, with an initial focus on the U.S. market before partnering with global biopharmaceutical companies. Founded in 2016, the company addresses unmet medical needs in the renal space by leveraging proprietary nanoparticle technology to improve drug potency and patient adherence.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage unicycive.com
Sector Healthcare IR page ir.unicycive.com
Tags
kidney disease, phosphate binders, acute kidney injury, chronic kidney disease, hyperphosphatemia, clinical-stage, nanoparticle technology, drug development, oxylanthanum carbonate, UNI-494, Spectrum Pharmaceuticals, Sphaera Pharma
Press page —

Metrics

Valuation  
Market cap $ 136.673M
Market cap (USD) $ 136.673M
P/E -2.90
PEG —
P/BV 2.60
P/S 202.48
P/OCF -4.69
P/FCF -4.66
Dividend yield —
Turnover / mcap —
Returns  
ROE -141.1%
ROI -87.7%
ROIC -73.1%
Profit margin —
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock —
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 21
Quality score -57.1%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue — — 675K 951K — —
Net profit -26.555M -36.729M -30.544M -18.058M -10.017M -2.264M
Free cash flow -31.341M -28.647M -18.295M -15.653M -5.796M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 5.77 — — 0.83 — —
P/FCF -4.07 — — -0.81 — —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — — 306,000 155,000 793,000 681,000 117,000
Cash and deposits (USD) 15,000 — 16.6M 455,000 9.7M 26.1M 29.2M
Right-of-use assets (USD) — — 305,000 152,000 766,000 645,000 108,000
Cash flow detail
Operating cash flow (USD) — -1.46M -5.77M -15.7M -18.3M -28.6M -31.3M
Purchases of property, plant and equipment (USD) — — -29,000 -2,000 -12,000 -72,000 -24,000
Change in payables (cash effect) (USD) — -68,000 1.24M 1.27M 1.28M 790,000 -2.51M
Dividends paid (cash effect) (USD) — — — — -900,000 -1.1M —
Interest paid (cash effect) (USD) — — — -6,000 -24,000 -12,000 —
Share-based compensation (USD) — 232,000 966,000 1.05M 1.77M 2.35M 2.64M
Free cash flow (OCF - PPE - intangibles) (USD) — — -5.8M -15.7M -18.3M -28.6M -31.3M
Income detail
Research and development expense (USD) — 1.02M 6.08M 12.4M 12.9M 20M 9.12M
↳ 5y CAGR +55.1%
Total comprehensive income (USD) — — — — — -36.7M -26.6M
Comprehensive income to owners (USD) — — — — — -36.7M -26.6M
Reported Aug 16, 2021 Mar 31, 2022 Mar 31, 2023 Mar 28, 2024 Mar 28, 2024 Mar 30, 2026 Mar 30, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

- New Drug Application (NDA) for oxylanthanum carbonate (OLC) accepted by the U.S. Food and Drug Administration (FDA), with an assigned Prescription Drug User Fee Act (PDUFA) date of March 25, 2027

- As of September 30, 2026, unaudited cash, cash equivalents, and marketable securities totaled $59 million, with expected runway beyond 2027, including the cost of a potential OLC launch

MOUNTAIN VIEW, Calif., November 16, 2026 — Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the third quarter ended September 30, 2026, and provided a business update.

“We believe that the FDA’s acceptance of our NDA resubmission for OLC marks an important step toward our goal of bringing this much-needed treatment to patients,” said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive.

October 21, 2026 7:05am EDT Download as PDF

  • Resubmission includes Chemistry, Manufacturing, and Controls (CMC) data from new drug product (DP) manufacturing vendor

MOUNTAIN VIEW, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of its New Drug Application (NDA) for oxylanthanum carbonate (OLC), the Company’s investigational oral phosphate binder for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. The NDA was resubmitted following a Complete Response Letter (CRL) received in June 2026. The FDA has deemed the OLC resubmission a Class II with a six-month review period from the resubmission date, and set a Prescription Drug User Fee Act (PDUFA) target action date of March 25, 2027.

“We are pleased that the FDA has accepted the resubmission of our NDA for OLC and assigned a PDUFA date,” said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. “This resubmission includes CMC data from a new third-party drug product manufacturing vendor. The new vendor’s facility was last inspected by the FDA in March 2024 and received ‘No Action Indicated’ status. We hope to continue working with the FDA toward potential approval of this important medication to patients with CKD on dialysis who need additional treatment options for managing hyperphosphatemia.”

The Company does not know whether the FDA will decide to conduct a pre-approval inspection of the new third-party DP vendor. Additionally, if the original third-party manufacturing vendor is inspected in the near term and finds that its facility complies with current Good Manufacturing Practice (cGMP), the Company plans to seek FDA alignment on a shorter approval timeline.

The Company resubmitted the NDA following the second CRL, which cited deficiencies previously identified at the original third-party manufacturer of the drug product, which the FDA had not been able to re-inspect during the prior submission review.

The timing and outcome of any FDA inspection of the original third-party vendor will be determined solely by the FDA.

The NDA is supported by data from three clinical studies (a Phase 1 study in healthy volunteers, a bioequivalence study in healthy volunteers, and a tolerability study of OLC in CKD patients on dialysis), multiple preclinical studies, as well as CMC data. The FDA did not raise any concerns regarding OLC’s preclinical or clinical data, including safety data, included in the original NDA submission.

About Oxylanthanum Carbonate

OLC is an investigational oral phosphate binder that leverages proprietary nanoparticle technology to deliver high phosphate binding potency, reducing the number and size of pills that patients must take to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. Its potential best-in-class profile may have meaningful patient adherence benefits over currently available treatment options as it requires a lower pill burden. Unicycive is seeking FDA approval of OLC via the 505(b)(2) regulatory pathway. OLC is protected by a strong global patent portfolio including issued patents on composition of matter with exclusivity until 2031, and with the potential for patent term extension until 2035.

About Hyperphosphatemia

Hyperphosphatemia is a serious medical condition that occurs in nearly all patients with End Stage Renal Disease (ESRD). Annually there are over 450,000 individuals in the U.S. that require medication to control their phosphate levels.1 Uncontrolled hyperphosphatemia is strongly associated with increased death and hospitalization for CKD patients on dialysis. Treatment of hyperphosphatemia is aimed at lowering serum phosphate levels via two means: (1) restricting dietary phosphorus intake; and (2) using, on a daily basis, and with each meal, oral phosphate binding drugs that facilitate fecal elimination of dietary phosphate rather than its absorption from the gastrointestinal tract into the bloodstream.

1Flythe JE. Dialysis-Past, Present, and Future: A Kidney360 Perspectives Series. Kidney360. 2023 May 1;4(5):567-568. doi: 10.34067/KID.0000000000000145.

About Unicycive Therapeutics

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit Unicycive.com

 and follow us on LinkedIn

 and X

.

Forward-looking statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern Unicycive's expectations, strategy, plans or intentions. These forward-looking statements are based on Unicycive's current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; Unicycive’s clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; Unicycive’s dependence on third parties for manufacturing; the possibility that FDA may require inspection of any vendor prior to approval, which could delay or prevent approval of its NDA; the risk that the inspection of the original or new third-party manufacturing vendor may not occur within a timeframe that benefits its regulatory timeline, or may result in adverse findings; risks related to business interruptions, which could seriously harm its financial condition and increase its costs and expenses; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; market acceptance of its products; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Unicycive’s Annual Report on Form 10-K for the year ended December 31, 2025, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Unicycive specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Contacts:

Kevin Gardner

LifeSci Advisors

[email protected]

Media Contact:

Unicycive Therapeutics

[email protected]

 

October 01, 2026 7:05am EDT Download as PDF

MOUNTAIN VIEW, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced the appointment of Meredith Manning, M.B.A., to its Board of Directors.

“We are very pleased to welcome Meredith to our Board of Directors. Her extensive commercialization experience, track record of building successful biopharmaceutical organizations, and leadership through successful product launches will be invaluable to Unicycive,” said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive Therapeutics. “We look forward to benefiting from Meredith’s strategic insight and first-hand experience as we advance OLC towards potential approval and prepare for the next stage of the Company’s growth.”

“I am honored to join Unicycive’s Board of Directors at such an important time for the Company,” said Ms. Manning. “With the recent NDA resubmission, Unicycive is advancing toward its goal of bringing oxylanthanum carbonate to patients and preparing for its transition to a commercial-stage company. I look forward to working with Shalabh and the Board to support the Company’s strategy and create long-term value for patients and shareholders.”

Ms. Manning will serve on each of the Audit, Compensation, and Nominating and Corporate Governance Committees, and will serve as the Chairperson of the Nominating and Corporate Governance Committee.

Ms. Manning has more than 25 years of global biopharmaceutical experience. Most recently, she served as Chief Commercial Officer of Soleno Therapeutics, Inc. from 2024 until its acquisition by Neurocrine Biosciences, Inc. in 2026. At Soleno, she built the commercial organization from inception and led the U.S. launch of VYKAT™ XR, the first FDA-approved treatment for hyperphagia in Prader-Willi syndrome. As a member of the executive team, she also contributed to asset evaluation, lifecycle planning and due diligence, and led the selection of ex-U.S. distribution partners.

Previously, Ms. Manning served as General Manager, and later, President, The Americas, and as a voting member of the U.S. Board of Directors of PharmaEssentia Corporation from 2020 to 2023. She built the U.S. organization from the ground up with general management and P&L responsibility for all U.S. functions. She was a key member of the team that secured FDA approval of BESREMi® (ropeginterferon alfa-2b-njft), led its U.S. commercial launch, and supported the company’s capital-raising efforts. She previously served as Chief Commercial Officer of resTORbio, Inc.

Earlier in her career, Ms. Manning served as Vice President, Global Marketing and Product Strategy Lead, Hemophilia, at Shire (formerly Baxter/Baxalta), where she led a seven-brand portfolio across more than 65 countries. She also held senior U.S. marketing and field leadership roles at Vertex Pharmaceuticals Incorporated, including the launch of INCIVEK® (telaprevir), and director-level roles in oncology business development, marketing and managed care at Pfizer Inc. Ms. Manning holds a B.A. in political science from The Colorado College and an M.B.A. from the University of Chicago Booth School of Business.

About Unicycive Therapeutics

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit Unicycive.com

 and follow us on LinkedIn

 and X

.

Forward-looking statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern Unicycive's expectations, strategy, plans or intentions. These forward-looking statements are based on Unicycive's current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; our dependence on third parties for manufacturing; the possibility that FDA may require inspection of any vendor prior to approval, which could delay or prevent approval of our NDA; the risk that the original third-party manufacturing vendor’s reinspection may not occur within a timeframe that benefits our regulatory timeline, or may result in adverse findings; risks related to business interruptions, which could seriously harm our financial condition and increase our costs and expenses; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; market acceptance of our products; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Unicycive’s Annual Report on Form 10-K for the year ended December 31, 2025, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Unicycive specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Contacts:

Kevin Gardner

LifeSci Advisors

[email protected]

Media Contact:

Unicycive Therapeutics

[email protected]

Prompts

Unicycive Therapeutics, Inc. (ticker UNCY), listed in United States.

ETFs Holding Unicycive Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
RESM 0.00% 28 $ 131.32 Jun 30, 2026
DFSU 0.00% 2,981 $ 10.851K Nov 12, 2026
DCOR 0.00% 3,419 $ 12.445K Nov 12, 2026